Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15

Background: The aim of the research is to study the human leukocyte antigen (HLA) class II allele frequencies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) associated with anti-neurofascin 155 (NF155) antibodies. Methods: Thirteen anti-NF155+ and 35 anti-NF155 negative (anti-NF...

Descripción completa

Detalles Bibliográficos
Autores: Martinez Martinez, Laura, Lleixà, Cinta|||0000-0002-9971-0584, Boera-Carnicero, Gemma, Cortese, Andrea, Devaux, Jérôme|||0000-0001-6383-4334, Siles, Ana M.., Rajabally, Yusuf, Martínez-Piñeiro, Alicia|||0000-0003-1988-606X, Carvajal, Alejandra, Pardo, Julio|||0000-0001-8807-1310, Delmont, Emilien, Attarian, Shahram, Diaz-Manera, Jordi|||0000-0003-2941-7988, Callegari, Ilaria, Marchioni, Enrico, Franciotta, Diego, Benedetti, Luana, Lauria, Giuseppe, Calle Martín, Óscar de la|||0000-0001-9717-053X, Juárez Rubio, Cándido|||0000-0003-2235-9893, Illa, Isabel|||0000-0002-2186-2684, Querol, Luis|||0000-0002-4289-8264
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:196948
Acceso en línea:https://ddd.uab.cat/record/196948
https://dx.doi.org/urn:doi:10.1186/s12974-017-0996-1
Access Level:acceso abierto
Palabra clave:CIDP
Antibodies
NF155
HLA DRB1*15
Descripción
Sumario:Background: The aim of the research is to study the human leukocyte antigen (HLA) class II allele frequencies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) associated with anti-neurofascin 155 (NF155) antibodies. Methods: Thirteen anti-NF155+ and 35 anti-NF155 negative (anti-NF155neg) CIDP patients were included in a casecontrol study. The frequencies of the DRB1 HLA allele were analyzed in all patients while DQ frequencies were only studied in patients sharing the DRB1*15 allele. In silico HLA-peptide binding and NF155 antigenicity, predictions were performed to analyze overlap between presented peptides and antigenic regions. Results: DRB1*15 alleles (DRB1*15:01 and DRB1*15:02) were present in 10 out of 13 anti-NF155+ CIDP patients and in only 5 out of 35 anti-NF155neg CIDP patients (77 vs 14%; OR = 20, CI = 4.035 to 99.13). DRB1*15 alleles appeared also in significantly higher proportions in anti-NF155+ CIDP than in normal population (77 vs 17%; OR = 16.9, CI = 4.434 to 57. 30). Seven anti-NF155+ CIDP patients (53%) and 5 anti-NF155neg CIDP patients had the DRB1*15:01 allele (OR = 7, p = 0.009), while 3 anti-NF155+ CIDP patients and none of the anti-NF155neg CIDP patients had the DRB1*15:02 allele (OR = 23.6, p = 0.016). In silico analysis of the NF155 peptides binding to DRB1*15 alleles showed significant overlap in the peptides presented by the 15:01 and 15:02 alleles, suggesting functional homology. Conclusions: DRB1*15 alleles are the first strong risk factor associated to a CIDP subset, providing additional evidence that anti-NF155+ CIDP patients constitute a differentiated disease within the CIDP syndrome.

Similares en LA Referencia